Premium
Pharmacometabolomics of Statin Response
Author(s) -
Krauss R M,
Zhu H,
KaddurahDaouk R
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.164
Subject(s) - simvastatin , statin , medicine , atorvastatin , inflammation , disease , atherosclerotic cardiovascular disease , pharmacology , cholesterol , bioinformatics , biology
Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma low‐density lipoprotein (LDL) concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD biomarkers. In the studies summarized here, we used complementary metabolomics platforms to define global effects of a statin (simvastatin) on metabolism and to identify markers indicative of mechanisms that contribute to variation in plasma LDL response to statin treatment. Clinical Pharmacology & Therapeutics (2013); 94 5, 562–565. doi: 10.1038/clpt.2013.164